SOPHiA CEO sells 51,442 shares, exercises options

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an exercise-and-sell transaction involving the company’s ordinary shares.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an exercise-and-sell transaction involving the company’s ordinary shares. He exercised 31,940 share options at an exercise price of $3.16 per share and sold a total of 51,442 ordinary shares in open-market trades at weighted average prices around $5.73–$5.84, in multiple transactions within disclosed ranges. These sales were made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following the transactions, he directly owns 3,601,493 ordinary shares and holds 4,709,536 derivative stock options across remaining grant tranches with varying exercise prices.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Camblong Jurgi

Role Chief Executive Officer

Sold 51,442 shs ($298K)

Approx. gross sale proceeds $298K

Approx. exercise cost $101K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	31,940	$0.00	$0.00
Sale	Ordinary Shares	18,129	$5.733	$104K
Exercise	Ordinary Shares	31,940	$3.16	$101K
Sale	Ordinary Shares	31,940	$5.8358	$186K
Sale	Ordinary Shares	1,373	$5.70	$8K

Holdings After Transaction: Share Option (Right to Buy) — 68,060 contracts (Direct); Ordinary Shares — 3,601,493 shares (Direct)

Footnotes (5)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.70 to $5.78, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.80 to $5.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The share options are fully vested and exercisable.
5. F5. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,709,536 derivative stock options across all remaining grant tranches with varying exercise prices.

Key Figures

Shares sold: 51,442 shares Option shares exercised: 31,940 shares Option exercise price: $3.16 per share +4 more

7 metrics

Shares sold 51,442 shares Total ordinary shares sold in open-market transactions on June 25–26, 2026

Option shares exercised 31,940 shares Ordinary shares acquired via option exercise on June 26, 2026

Option exercise price $3.16 per share Conversion or exercise price for exercised share options

Sale price range (block 1) $5.70–$5.78 per share Price range for one set of weighted average sales

Sale price range (block 2) $5.80–$5.94 per share Price range for another set of weighted average sales

Shares owned after transaction 3,601,493 shares Direct ordinary share holdings following reported transactions

Remaining derivative options 4,709,536 options Aggregate derivative stock options across all remaining grant tranches

Key Terms

Rule 10b5-1(c), weighted average price, Share Option (Right to Buy), derivative stock options

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

derivative stock options financial

"holds an aggregate total of 4,709,536 derivative stock options across all remaining grant tranches"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SOPHiA GENETICS (SOPH) CEO Jurgi Camblong report in this Form 4?

He reported an exercise-and-sell transaction in SOPHiA GENETICS ordinary shares. The filing shows option exercises and open-market sales, along with his updated direct share ownership and remaining derivative stock option holdings after these transactions.

How many SOPHiA GENETICS shares did the CEO sell according to the Form 4?

The CEO sold 51,442 ordinary shares of SOPHiA GENETICS in open-market transactions. These sales occurred at weighted average prices, with individual trades executed within specified price ranges disclosed in the footnotes to the filing.

At what prices were the SOPHiA GENETICS shares sold in this insider transaction?

The reported sale prices are weighted averages around $5.70 to $5.94 per share. Footnotes explain that the shares were sold in multiple transactions within those ranges, and detailed trade breakdowns are available upon written request.

How many options did the SOPHiA GENETICS CEO exercise, and at what exercise price?

He exercised 31,940 share options with a conversion or exercise price of $3.16 per share. The corresponding derivative entry notes these are share options (right to buy) that were fully vested and exercisable at the time of the transaction.

What are the CEO’s SOPHiA GENETICS holdings after these transactions?

After the reported transactions, he directly owns 3,601,493 ordinary shares of SOPHiA GENETICS. A footnote also states that he holds 4,709,536 derivative stock options across remaining grant tranches with varying exercise prices.

Were the SOPHiA GENETICS CEO’s share sales made under a trading plan?

Yes. A footnote specifies that at least one of the transactions was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans are pre-arranged and execute trades automatically according to preset conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/25/2026		S		1,373(1)	D	$5.7	3,619,622	D
Ordinary Shares	06/26/2026		S		18,129(1)	D	$5.733(2)	3,601,493	D
Ordinary Shares	06/26/2026		M		31,940(1)	A	$3.16	3,633,433	D
Ordinary Shares	06/26/2026		S		31,940(1)	D	$5.8358(3)	3,601,493	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.16	06/26/2026		M			31,940	(4)	11/29/2028	Ordinary Shares	31,940	$0	68,060(5)	D

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.70 to $5.78, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.80 to $5.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The share options are fully vested and exercisable.

5. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,709,536 derivative stock options across all remaining grant tranches with varying exercise prices.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)